Floatz logo

Brostallicin

Small Intestine Cancer

European Organisation for Research and Treatment of Cancer - EORTCSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

21 Active assets in the Small Intestine Cancer cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
National Cancer Institute (NCI)
Phase 2BB
ETOPOSIDE
Cancer Research UK
Phase 2BB
VINCRISTINE SULFATE
Cancer Research UK
Phase 2BB
FILGRASTIM
Cancer Research UK
Phase 2BB
PREDNISONE TABLETS
City of Hope Medical Center
Phase 2B

View all 50 →

Same molecule, other indications

Brostallicin is also rated in:

triple-negative breast carcinomaDormant
B
Indicative ·
57 / 100
View asset →
sarcomaDormant
CCC
Indicative ·
51 / 100
View asset →
plasma cell myelomaDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →